











































Ischemic stroke (IS) is a complex age-related disease 
with high mortality and long-term disability. Despite 
current attention to risk factors and preventive 
treatment, the number of stroke cases has risen in recent 
decades, likely because the aging population has 
increased. Stroke pathogenesis involves a number of 
different disease processes as well as interactions 
between environmental, vascular, systemic, genetic, and 
central nervous system factors [1]. 
 
 










































In recent years, however, incidence of stroke has also 
increased among younger adults [2,3]. Approximately 
10% of IS occurs in individuals younger than 50 years, 
which is called “young stroke” [4,5]. This increase is 
often attributed to a high prevalence of unusual, rare 
conditions or to nontraditional risk factors such as 
migraine, illicit drug use, oral contraceptives, pregnancy 
and patent foramen oval. In older patients, stroke remains 
associated with the traditional risk factors: hypertension, 
hypercholesterolemia, diabetes mellitus, and obesity [6]. 





















Ischemic stroke  is associated with aging.  It  is possible  to predict chronological age by measuring age‐related
changes  in  DNA  methylation  from  multiple  CpG  sites  across  the  genome,  known  as  biological  age.  The




used  to  measure  DNA  methylation  in  CpG  sites  in  both  groups,  and  biological  age  was  estimated  using
methylation values of specific CpGs. Ischemic stroke patients were biologically an average 2.5 years older than
healthy  controls  (p‐value=0.010).  Stratified  by  age  tertiles,  younger  stroke  patients  (≤57  years  old)  were
biologically  older  than  controls  (OR=1.19;  95%CI  1.00‐1.41,  p‐value=0.046).  The  older  groups  showed  no
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The epigenetic marker that has been studied most 
extensively is DNA methylation (DNAm), which is 
essential for regulation of gene expression. This 
mechanism consists of the covalent addition of a methyl 
group to a cytosine nucleotide, primarily in the context 
of a CpG dinucleotide. This dinucleotide is quite rare in 
mammalian genomes (~1%) and is clustered in regions 
known as CpG islands. Methylation of the CpG island is 
associated with gene silencing. DNAm is dynamic, 
varies throughout the life course, and its levels are 
influenced by lifestyle and environmental factors, as 
well as by genetic variation [7]. Given its dynamic 
nature, epigenetics has been referred to as the interface 
between the genome and the environment [8]. 
 
Age-related changes in DNA methylation are well 
documented, and two recent studies used methylation 
measured from multiple CpGs across the genome to 
predict chronological age in humans [9,10]. Hannum et 
al. [9] created an age predictor from whole blood DNA, 
based on a single cohort of 656 individuals aged 19 to 
101 years. Horvath developed a multi-tissue age 

































studies [10]. Both models are based on the Illumina 
BeadChip. The difference between chronological age 
and methylation-predicted age, defined as average age 
acceleration (Δage), can be used to determine whether 
the DNAm age is consistently higher or lower than 
expected. These age predictors are influenced by 
clinical and lifestyle parameters, they are predictive of 
all-cause mortality, indicating that they are more 
suggestive of biological age than of chronological age 
[11–14]. 
 
Age is one of the main risk factors for stroke. We 
hypothesized that biological age would be even more 
closely associated with stroke risk, and that “young 
stroke” patients may be undergoing accelerated aging, 




We examined a cohort of 123 individuals, 41 controls 
and 82 patients with IS, matched by chronological age. 
The clinical and demographic characteristics of the 






































 Controls IS p-value 
 N=41 N=82  
Age* 62.8(14.2) 63.9 (10.3) 0.621 
Sex, female, n (%) 20 (48.8) 37 (45.1) 0.701 
Hyperlipidemia 20 (48.8) 44 (53.7) 0.610 
Hypertension, n (%) 19 (46.3) 54 (65.9) 0.038 
Diabetes, n (%) 7 (17.1) 30 (36.6) 0.026 
Coronary heart disease, n (%) 1 (2.4) 8 (9.8) 0.142 
Atrial fibrillation, n (%) 2 (4.9) 24 (29.3) 0.002 
BMI, Kg/m2‡ 28.3 (4.8) 29.0 (5.2) 0.523 
Smoking habit, n (%):    
Current/Former (<5 years) 20 (48.8) 47 (57.3) 
0.370 
Never smokers 21 (51.2) 35 (42.7) 
Ischemic stroke etiology, n (%)    
Large-artery atherosclerosis - 9 (11.0)  
Small-artery disease - 39 (47.6)  
Cardioembolism - 34 (41.5)  
Hannum DNAm age (years) 63.9 (11.9) 67.2 (8.8) 0.081 
Hannum difference 1.1 (5.5) 3.3 (5.7) 0.041 
Horvath DNAm age (years) 58.2 (10.8) 60.7 (10.0) 0.204 
















































We initially used two approaches described in the 
literature to predict biological age, the Hannum and 
Horvath methods. The average biological age of controls 
showed a mean Hannum-predicted age higher than their 
chronological ages by a mean of 1.1 years (SD=5.5); 
their Horvath-predicted age was lower than their chrono-
logical ages by 4.6 years (SD=5.8). In patients with IS, 
we observed a Hannum-predicted age higher than their 
chronological age by a mean of 3.3 years (SD=5.7), 
statistically significant compared to controls (p-
value=0.04). Their Horvath-predicted age was lower than 












































DNAm age had a strong positive correlation with 
chronological age in control samples (0.93 for both 
Hannum and Horvath methods, and 0.94 between the 
Hannum- and Horvath-predicted ages). In IS cases, the 
correlations were lower (0.83 for the Hannum method, 
0.72 for the Horvath method, and 0.82 between the two 
(Figure 1). Although both age predictors showed high 
accuracy in our samples, Hannum DNAm age 
performed better, with fewer differences in chrono-
logical age in controls and better correlation in patients 





www.aging‐us.com                    2657                                                       AGING (Albany NY) 
Regression lines through sample values stratified by IS 
cases and controls suggest that IS cases have a higher 
DNAm (biological) age than controls using both the 
Hannum and Horvath methods (Figure 2-A).  Moreover, 
we calculated average age acceleration (Δage) for both age 
predictor methods, defined by the average difference 
between DNAm age and chronological age. Δage is not 















































p=0.47; Δage Horvath, r=0.009, p=0.92), on the other 
hand it is correlated to stroke status with Hannum Δage 
(r=0.24, p=0.008) and close to significance with Horvath 
Δage (r=0.133 p=0.143). ANOVA test showed that 
biological age of IS cases was older than controls, with a 
significant average Hannum Δage of 2.5 years (SD=4.9), 
p=0.008 and Horvath Δage of 1.7 years (SD=7.0), 






















































 Model 1 Model 2 Model 3 Model 4 
Control vs IS OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value
ΔageHannum 1.13 (1.03-1.23) 0.010 1.13 (1.03-1.24) 0.010 1.13 (1.02-1.24) 0.015 1.13 (1.003-1.26) 0.045 
Δage Horvath 1.05 (0.98-1.12) 0.145 1.05 (0.98-1.12) 0.151 1.07 (0.99-1.15) 0.086 1.06 (0.97-1.15) 0.223 
Figure 2. DNA methylation Age (A) Hannum and Horvath versus chronological age in blood samples. Grey and black circles
in  the scatterplot denote samples  from controls and cases,  respectively. The grey  line  represents a  linear  regression  line
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Four logistic regression models were considered. Model 
1 was the raw model with no adjustments. Model 2 was 
logistic regression model adjusted by sex, because sex 
variable was significantly associated to Δage Hannum (p-
value=0.029). Finally, model 3 (full model) was 
adjusted by sex, smoking habit, atrial fibrillation, 
hypertension and diabetes mellitus. According to these 
models, IS cases showed a significant Hannum Δage 
effect, being biologically older than controls of the 
same chronological age (Table 2). The adjusted model 3 
showed OR=1.14 (95%CI 1.03-1.26), p-value=0.015. 
Model 4 adjusted by model 3 variables and blood cell 
proportion associated Hannum and Horvath DNAm age 
(Supplemental Table S1). Hannum Δage was statistically 
significant OR=1.13 (95%CI 1.003-1.26), p-
value=0.045. The Horvath method yielded results close 
to statistical significance in all four models, a trend 



























We stratified the cohort by age tertiles, considering 
young individuals those ≤57 years old, mid-aged 
between 58-71 years old and elderly as ≥72 years old, 
and grouped the mid-aged and elderly groups together 
as older adults to get more statistical power. The 
clinical and demographic characteristics by age group 
are shown in Table 3. We continued our study using the 
Hannum age predictor because it was statistically 
significant in the previous analysis. Logistic analysis 
revealed that the biological age of young IS cases was 
significantly older than controls for both model 1 
(OR=1.19 [95%CI 1.00-1.41], p-value=0.041) and 
model 2, (OR=1.19 [95%CI 1.00-1.41], p-value=0.046) 
(Figure 3), but not for the fully adjusted model 
(OR=1.13 [95%CI 0.97-1.32], p-value=0.131). The 
older IS groups were more similar to the control group 
in biological age, but the difference was close to 




The sensitivity analysis evaluating which age predictor 
performed better in our study determined that the 
Hannum predictor was superior. This is likely because 
this method is constructed on the basis of DNA 
methylation data from whole blood, like our data, while 
the Horvath method is constructed on a range of 
different tissues and cell types [11]. 
 
A growing body of evidence suggests that many 
manifestations of aging are epigenetic [15,16]. In 
particular, DNA methylation associates with 
chronological age over long time scales and changes in 
methylation have been linked to complex age-associated 
diseases such as metabolic  disease  and  cancer [17–23]. 
One possible explanation for this association could lie 
in the accumulation of environmental exposures that 
may contribute to epigenetic changes with age. Changes 
in the functionality of epigenetic machinery in addition 
to exposure of the genome to environmental factors 
could contribute to increasing epigenetic diversity with 
age [24,25]. Many studies have found a mean decrease 
in blood DNA methylation with increasing age. It has 
been reported that DNA obtained from a 103-year-old 
donor was more unmethylated overall than DNA from 
the same cell type obtained from a neonate, showing 
that DNA methylomes differ at the two extremes of the 
human lifespan [26,27]. Environmental and stochastic 
factors are associated to epigenetic changes with age, 
and two events, epigenetic drift and epigenetic clock, 
contribute  to  age-related   DNA  methylation  changes. 
Epigenetic drift represents the tendency for increasing 
discordance between epigenomes over time but these 
differences are not consistent across individuals [27]. In 
fact, has been found that methylation marks in identical 
twins differ increasingly as a function of age, both in 
genome variation and lifetime environmental exposures 
[18,28]. On the other hand, the epigenetic clock 
represents those sites that are associated with age across 
individuals and can be used to predict the age of an 
individual [24,29–31]. 
 
Incidence of IS has been strongly correlated with 
increasing age [32]. Approximately 10% to 15% of all 
IS occurs in young adults. The prevalence of standard 




the  scatterplot  denote  samples  from  controls  and  cases,
respectively. The grey  line  represents a  linear  regression  line
through  control  samples.  The black dashed  line  represents  a
linear  regression  line  through  IS  cases, OR=1.13  (95%CI 1.03‐
1.23), p‐value 0.01. 
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patients differs from that in older patients, with the 
prevalence of hypertension, diabetes mellitus, obesity, 
lipid disorders, congenital heart disease, and smoking 
increasing with age [2,32,33]. In this context, the 
increase in biological age, compared to healthy controls, 
echoes the burden of exposures --vascular risk factors, 
lifestyle habits, environment-- that leads to an 
epigenetic profile similar to elderly people. 
 
Previous studies have shown that epigenetic age relates 
to cognitive status, physical fitness, mortality, HIV 
infection, Parkinson Disease and Down Syndrome 










































hypomethylation in IS cases compared to controls and 
age-associated DNA hypomethylation using the LUMA 
assay [39]. Now, we find for the first time that epigenetic 
age in patients with IS averages 2.5 years older than in 
controls, but is especially patenting in young stroke 
patients. 
 
A strength of our study is that we evaluated two distinct 
epigenetic biomarkers of aging. The association 
between age acceleration and IS was stronger for the 
blood-based Hannum method, although the multitissue-
based Horvath method showed similar (but 
nonsignificant) results. Moreover, this is the first study 













































 Young ≤57 years Εlderly ≥58 years 
 Controls IS p-value Controls IS p-value 
N 16 25  25 57  
Sex, female, n(%) 7 (43.8) 5 (20) 0.103 13 (52.0) 32 (56.1) 0.729 
Hyperlipidemia, n(%) 6 (37.5) 14 (56) 0.248 14 (56.0) 30 (52.6) 0.814 
Hypertension, n(%) 3 (18.8) 14 (56) 0.018 16 (64.0) 40 (70.2) 0.580 
Diabetes, n(%) 1 (6.3) 6 (24) 0.141 6 (24.0) 24 (42.1) 0.117 
Coronary heart disease, n(%)* 0 1 (4.0) 0.418 1 (4.0) 7 (12.3) 0.245 
Atrial fibrillation, n (%) 0 3 (12) 0.150 2 (8.0) 21 (36.8) 0.007 







Smoking habit, n (%):       
      Current/Former (<5 years) 11 (68.8) 22 (88) 
0.129 
9 (36) 25 (43.9) 
0.506 




Table  4.  Logistic models  that  regressed  IS  status,  stratified  by  age, on Hannum  age  acceleration 






Model 1 Model 2 Model 3 
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
All 1.13 (1.03-1.23) 0.010 1.13 (1.03-1.24) 0.010 1.13 (1.02-1.24) 0.015 
≤57 1.19 (1.01-1.41) 0.041 1.19 (1.00-1.41) 0.046 1.13 (0.97-1.32) 0.131 
≥58 1.09 (0.98-1.22) 0.111 1.11 (0.99-1.24) 0.083 1.12 (0.99-1.27) 0.064 
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Some limitations of the study should be considered. 
Although the sample size was appropriate to detect 
findings consistently and significantly, the study may be 
underpowered to reach statistical significance for some 
analyses with the Horvath age predictor or further 
stratified sub-analyses. Second, we measured DNA 
methylation in peripheral blood cells. Methylation 
levels of some CpGs/regions are tissue-specific [40] and 
we might have lost some signals by not choosing 
specific tissues where biological aging could have a 
higher impact on risk for stroke. However, methylation 
patterns of whole blood have been reported as a good 
proxy for methylation levels from a specific site of 
action [41,42]. 
 
In conclusion, we found that IS status was associated 
with a significant increase in Hannum DNA methyla-
tion, likely as a consequence of the accumulation of 
cardiovascular risk factors, and near signification with 
Horvath method. Patients with IS were biologically 
older than controls, a difference that was more obvious 
in young stroke. This could open up the possibility of 






The study included Caucasian patients prospectively 
recruited and analyzed retrospectively. 
 
From 2009 to 2012, 82 patients with IS where recruited 
in Hospital del Mar in Barcelona, Spain, and were 
included in the BASICMAR Register (Ministerio de 
Sanidad y Consumo, Instituto de Salud Carlos III; FIS 
No. PI051737) [43,44]. Inclusion criteria in BASICMAR 
cohorts were as follows: (1) first-ever IS, (2) brain 
imaging with CT or MRI, (3) availability of clinical data 
supporting the assigned stroke subtype according to 
TOAST classification [45], (4) absence of intracranial 
hemorrhage, neoplasms, demyelinating and autoimmune 
diseases, and vasculitides. All patients were assessed and 
classified by a neurologist and were included in the study 
by consecutive order of recruitment. 
 
Control samples (N=41) were obtained from the Girona 
Heart Registry (REGICOR, which stands for REgistre 
GIroni del COR), a population-based cohort recruited in 
the province of Girona, about 100 km from Barcelona. 
This register includes a randomized representative 
sample of men and women of the province [46]. 
 
The study was approved by the local ethics committee, 
CEIC-Parc de Salut Mar, and participants gave written 
informed consent. The study was conducted according 
to the principles expressed in the Declaration of 
Helsinki and relevant legislation in Spain. 
 
Demographic and vascular risk factor variables 
 
In accordance with international guidelines, data on 
vascular risk factors analyzed were obtained from direct 
interview of the patient, relatives and caregivers, and 
from medical records. Examinations were performed 
and standardized questionnaires administered during the 
hospitalization by a team of neurologists and reviewed 
by an additional neurologist. 
 
We recorded age, sex, and vascular risk factors using a 
structured questionnaire, as follows: arterial 
hypertension (HT), defined as systolic blood pressure 
(SBP) ≥140 mmHg or diastolic (DPB) ≥90 mmHg 
recorded  from more than 2 measurements previous to 
the acute event, a physician’s diagnosis, or use of 
medication; hyperlipidemia, defined as a physician’s 
diagnosis, use of medication, serum cholesterol 
concentration >220 mg/dL, low-density lipoprotein 
cholesterol (LDL) >130 mg/dL, or serum triglyceride 
concentration >150 mg/dL; diabetes mellitus (DM), 
defined as evidence of two or more fasting blood 
glucose values ≥126 mg/dl, use of diabetes medication, 
or a physician’s diagnosis; coronary heart disease 
(CHD),defined as documented history of angina 
pectoris or myocardial infarction; atrial fibrillation (AF) 
(documented history or diagnosis during hospitalize-
tion); and self-reported smoking habit. During 
hospitalization, lymphocyte count and body mass index 
(BMI) were recorded and TOAST criteria were used to 
classify IS subtype [45], according to standardized 
protocol. 
 
Peripheral blood collection and DNA extraction 
 
DNA samples were extracted from whole peripheral 
blood collected in 10 mL EDTA tubes. The Chemagic 
Magnetic Separation Module I system (Chemagen) and 
the Autopure LS (Qiagen) were used for DNA isolation 
in the BASICMAR patient cohort; only the Autopure 
LS (Qiagen) was used in the REGICOR cohort. In both 
cohorts, genome-wide DNA methylation was assessed 
using the Illumina HumanMethylation450 Beadchip. 
DNA extractions were performed at the same time and 
stored together at −20°C. DNA concentrations were 
quantified using the Picogreen assay and Nanodrop 
technology. The quality of DNA samples was visualized 
in agarose gels. We tested whether DNA isolation 
method was a confounder in our methylation analysis; 
no statistical differences were observed. 
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Array-based DNA methylation analysis with 
Infinium HumanMethylation 450k 
 
Genomic DNA (1 µg) was bisulfite-converted using the 
EZ-96 DNA Methylation Kit (Zymo Research, Orange, 
CA, USA) according to the manufacturer’s procedure 
and recommended alternative incubation conditions 
when using the Illumina Methylation Assay. 
 
Genome-wide DNA methylation was assessed using the 
Illumina HumanMethylation450 Beadchip (Illumina 
Netherlands, Eindhoven, Netherlands) following the 
manufacturer’s protocol with no modifications. The 
arrays were scanned with the Illumina HiScan SQ 
scanner. These processes were carried out in Progenika 
Biopharma in Bizkaia, Spain. 
 
Data pre-processing and normalization 
 
Data were pre-processed using standardized pipelines 
[47,48]. Sample and CpG quality controls and the 
statistical analysis were performed as described in 
Soriano-Tarraga et al [44]. Initial quality control of 
sample data was conducted using GenomeStudio 
version 2011.1 (Illumina, San Diego, CA, USA). Before 
analysis methylation values were corrected for 
background values and then normalized by SWAN using 
minfi Bioconductor package [48] and then, β values 
were transformed using a variance stabilization 
transformation to methylation M-values. 
 
We used a previously published Houseman algorithm to 
infer white blood cell counts from DNA methylation 
data [51] and Horvath online calculator [10]. 
 
DNA methylation age and epigenetic clock 
 
DNA methylation (DNAm) age, also known as 
“epigenetic age” or “biological age”, was calculated 
using the DNA methylation levels of whole blood 
DNA. Two measures of DNA methylation age were 
calculated. The Horvath method uses 353 probes 
common to the Illumina 27 K and 450 K Methylation 
arrays using data from a range of tissues and cell types 
[10]. Methylation age was determined using the online 
calculator (https://labs.genetics.ucla.edu/horvath/htdocs 
dnamage/). The Hannum method is based on 71 
methylation probes from Illumina 450 K Methylation 
array, derived as the best predictors of age using data 
generated from whole blood [9]. DNA methylation age 
was calculated as the sum of the beta values 
multiplied by the reported effect sizes for the 
Hannum predictor. 
 
The concept of age acceleration (Δage) is defined as the 
residuals from the linear regression of DNAm age on 
chronological age in control samples [11]. This measure 
of Δage is not correlated with chronological age and 
takes on a positive value for samples whose DNAm age 




Baseline characteristics of IS patients and controls were 
compared using t-test for continuous variables and chi-
square for categorical variables. We calculated the 
Pearson correlation of DNAm age and chronological 
age for all the samples and stratified by IS patients and 
controls. Sensitivity analysis was carried out to assess 
which age predictor performed better in our study, in 
order to simplify and improve the statistical model. 
 
Four logistic models were analyzed. In Model 1 (raw 
model), IS status was regressed on Hannum age 
acceleration. Model 2 was model 1 adjusted by sex. 
Model 3 was model 1 adjusted by atrial fibrillation, 
diabetes mellitus, hypertension, and smoking habit, and 
stratified by age using tertile cut points (≤57,58-71 and 
≥72 years). Moreover, model 4 was performed, adjusted 
by previous variables (atrial fibrillation, diabetes 
mellitus, hypertension, and smoking habit) and blood 
cell proportion associated to Hannum age acceleration 
(NK, monocytes, CD4+ T cells, naïve CD8 T cells and 
CD8+CD28-CD45RA) and Horvath age acceleration 
(NK, monocytes, CD8+ T cells, naïve CD8 and CD4 T 
cells). We tested for differences in DNAm Age using all 
four logistic models 
 
All statistical analyses were performed using R 
statistical package, version 3.2 [52], STATA and SPSS 
version 18.0.  The following packages were utilized in 
R: minfi, sva and limma [49,53,54]. Statistical 
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